BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...database, at least one other company is currently developing S100-targeting therapies in cancer and inflammation. Active Biotech...
BioCentury | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

...a medical meeting. Teva has exclusive, worldwide rights to the oral quinoline-3-carboxamide immunomodulator from Active. Active Biotech AB...
...atrophy Status: Phase II data Milestone: NA Chris Lieu Nerventra (Brand), 5062 (Compound #), laquinimod (Generic), SAIK-MS (Informal) Active Biotech AB Teva...
BioCentury | Jan 9, 2018
Finance

Stars in China

...dipeptide cleaved from human serum albumin. The biotech ended the year valued at $309 million. Active Biotech AB...
...to treat Duchenne muscular dystrophy (DMD) caused by a nonsense mutation Companies and Institutions Mentioned Active Biotech AB...
...bellwethers.” BioCentury (2018) Cukier-Meisner, E. “Car dealing.” BioCentury (2018) Amran Gowani, Senior Editor, Research & Analytics Ampion ANB020 cabiralizumab CART-BCMA laquinimod LCAR-B38M Mongersen Opdivo PARP inhibior Yescarta Zejula Active Biotech AB Ampio...
BioCentury | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

...Laquinimod also missed the secondary endpoint of improving time to confirmed disability progression vs. placebo. Active Biotech...
...relapsing-remitting multiple sclerosis (RRMS) (see BioCentury, May 12 ). Laquinimod is an oral quinoline-3-carboxamide immunomodulator. Active Biotech AB...
...of new T2 lesions and extended MRI data Status: Phase II data Milestone: NA Jaime De Leon laquinimod Nerventra SAIK-MS Active Biotech AB Teva...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...products being developed by partner Inspiration Biopharmaceuticals Inc. and prostate cancer therapy tasquinimod from partner Active Biotech AB...
...take those risks.” David Meek, Ipsen The second failure was tasquinimod, which Ipsen in-licensed from Active Biotech...
...are expected to start Phase I testing in 2019 for spasticity. Companies and Institutions Mentioned Active Biotech AB...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...3 to treat RCC. Eight companies in the sub-$500 million band lost 70% or more. Active Biotech AB...
...quality of life, increased risk of infection and inadequate manufacturing controls Companies and Institutions Mentioned Active Biotech AB...
...Spring, Md. XBiotech Inc. (NASDAQ:XBIT), Austin, Texas Meredith Durkin Wolfe, Associate Editor, Research & Analytics eptinezumab Evenity indoximod Kevzara laquinimod Oral neratinib Pexa-Vec tivozanib vadastuximab talirine Xilonix Active Biotech AB Alder...
BioCentury | Jun 21, 2017
Company News

Management tracks

...was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

...and atherosclerotic lesion size. Next steps could include testing other S100A9 inhibitors in the models. Active Biotech AB...
...in Phase II testing for systemic lupus erythematosus (SLE) and Phase I for systemic sclerosis. Active Biotech AB...
...progressive multiple sclerosis (PPMS) and Phase II for treat Crohn's disease and Huntington's disease (HD). Active Biotech...
BioCentury | May 12, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS trial

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod...
...is continuing clinical studies of the product in primary progressive MS and Huntington's disease (HD). Active Biotech AB...
...time to CDP after ≥6 and ≥9 months Status: Phase III data Milestone: NA Jaime De Leon laquinimod SAIK-MS Active Biotech AB Teva...
BioCentury | May 5, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS study

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said laquinimod (SAIK-MS) missed the primary endpoint...
...lost SEK0.40 to SEK17.70 on Friday. The partners announced CONCERTO's results after European market hours. Becky Simon laquinimod SAIK-MS Active Biotech AB Teva...
Items per page:
1 - 10 of 333
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

...database, at least one other company is currently developing S100-targeting therapies in cancer and inflammation. Active Biotech...
BioCentury | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

...a medical meeting. Teva has exclusive, worldwide rights to the oral quinoline-3-carboxamide immunomodulator from Active. Active Biotech AB...
...atrophy Status: Phase II data Milestone: NA Chris Lieu Nerventra (Brand), 5062 (Compound #), laquinimod (Generic), SAIK-MS (Informal) Active Biotech AB Teva...
BioCentury | Jan 9, 2018
Finance

Stars in China

...dipeptide cleaved from human serum albumin. The biotech ended the year valued at $309 million. Active Biotech AB...
...to treat Duchenne muscular dystrophy (DMD) caused by a nonsense mutation Companies and Institutions Mentioned Active Biotech AB...
...bellwethers.” BioCentury (2018) Cukier-Meisner, E. “Car dealing.” BioCentury (2018) Amran Gowani, Senior Editor, Research & Analytics Ampion ANB020 cabiralizumab CART-BCMA laquinimod LCAR-B38M Mongersen Opdivo PARP inhibior Yescarta Zejula Active Biotech AB Ampio...
BioCentury | Dec 8, 2017
Clinical News

Active, Teva's laquinimod misses in Phase II for PPMS

...Laquinimod also missed the secondary endpoint of improving time to confirmed disability progression vs. placebo. Active Biotech...
...relapsing-remitting multiple sclerosis (RRMS) (see BioCentury, May 12 ). Laquinimod is an oral quinoline-3-carboxamide immunomodulator. Active Biotech AB...
...of new T2 lesions and extended MRI data Status: Phase II data Milestone: NA Jaime De Leon laquinimod Nerventra SAIK-MS Active Biotech AB Teva...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...products being developed by partner Inspiration Biopharmaceuticals Inc. and prostate cancer therapy tasquinimod from partner Active Biotech AB...
...take those risks.” David Meek, Ipsen The second failure was tasquinimod, which Ipsen in-licensed from Active Biotech...
...are expected to start Phase I testing in 2019 for spasticity. Companies and Institutions Mentioned Active Biotech AB...
BioCentury | Jul 7, 2017
Finance

Onward and upward

...3 to treat RCC. Eight companies in the sub-$500 million band lost 70% or more. Active Biotech AB...
...quality of life, increased risk of infection and inadequate manufacturing controls Companies and Institutions Mentioned Active Biotech AB...
...Spring, Md. XBiotech Inc. (NASDAQ:XBIT), Austin, Texas Meredith Durkin Wolfe, Associate Editor, Research & Analytics eptinezumab Evenity indoximod Kevzara laquinimod Oral neratinib Pexa-Vec tivozanib vadastuximab talirine Xilonix Active Biotech AB Alder...
BioCentury | Jun 21, 2017
Company News

Management tracks

...was chief human resources officer at Shire plc (LSE:SHP; NASDAQ:SHPG). Neurodegenerative, inflammation and cancer company Active Biotech AB...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

...and atherosclerotic lesion size. Next steps could include testing other S100A9 inhibitors in the models. Active Biotech AB...
...in Phase II testing for systemic lupus erythematosus (SLE) and Phase I for systemic sclerosis. Active Biotech AB...
...progressive multiple sclerosis (PPMS) and Phase II for treat Crohn's disease and Huntington's disease (HD). Active Biotech...
BioCentury | May 12, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS trial

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) and partner Active Biotech AB (SSE:ACTI) said once-daily 0.6 mg laquinimod...
...is continuing clinical studies of the product in primary progressive MS and Huntington's disease (HD). Active Biotech AB...
...time to CDP after ≥6 and ≥9 months Status: Phase III data Milestone: NA Jaime De Leon laquinimod SAIK-MS Active Biotech AB Teva...
BioCentury | May 5, 2017
Clinical News

Teva's laquinimod fails Phase III RRMS study

...Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and partner Active Biotech AB (SSE:ACTI) said laquinimod (SAIK-MS) missed the primary endpoint...
...lost SEK0.40 to SEK17.70 on Friday. The partners announced CONCERTO's results after European market hours. Becky Simon laquinimod SAIK-MS Active Biotech AB Teva...
Items per page:
1 - 10 of 333